-
2025 HDBuzz Prize: MR-“why” am I feeling this way? How MRI is helping us understand why people with HD may sometimes be unaware of their symptoms
Latest News
-
PROOF in the Publishing: Slicing the Data on Pridopidine
Pridopidine has been tested as a potential HD treatment over decades. The large PROOF-HD trial did not meet its main goals, but its results are now published. Publication makes the full data available, helping the HD community learn from the study.
-
Vaccines and HD
Many HD families have questions about vaccination for the coronavirus – RNA sounds scary! HDBuzz helps unpack the headlines about vaccine safety and HD.
-
GPR52: Exploring a new way to lower huntingtin
A Chinese research team developed a new way to lower huntingtin protein indirectly, by targeting a protein called GPR52. The molecules they designed were protective in cells and in mice with HD.
-
Uncovering the dark side of DNA repair to design HD treatments
A gene called MSH3 helps to repair our DNA, but in HD it can slip up and cause CAG repeats to lengthen. Researchers have uncovered new information about how MSH3 activity is controlled, opening the door to new therapeutic avenues.
-
Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2
The 2020 virtual HSG conference HD in Focus continues on Day 2 with a focus on clinical trials and drugs in development.
-
Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1
Read our breakdown of some of the talks and presentations at day 1 of the Huntington Study Group (HSG) 2020 annual conference: HD in focus
-
Treatment for neurological disorder could be repurposed for Huntington’s disease patients
While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation.
-
Updates from the EHDN Plenary Meeting 2020
Read our summary of the latest updates from the EHDN Plenary Meeting 2020
-
Sad news from the SIGNAL study: pepinemab does not influence HD symptoms
The SIGNAL study did not meet its key clinical goals for #HuntingtonsDisease to slow or improve HD symptoms, but the results are still informative for the HD community and other fields.
-
When genes are unstable: targeting somatic instability in HD
CAG repeats expand in some parts of the body and brain as people with HD get older, a phenomenon known as somatic instability. Learn more about how researchers are exploring somatic instability and DNA repair to design therapies for HD.
-
Working as a team: Changes in brain development mean some brain regions may be slacking off
Scientists use human fetal tissue to look at HD brain development. But what do developmental changes mean when symptoms don’t occur until decades after birth?